A Phase 2 study of TAS-115 in patients with IPF
Phase 2
Completed
- Conditions
- Idiopathic pulmonary fibrosis
- Registration Number
- JPRN-jRCT2080223842
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Provided written informed consent
2. Confirmed IPF within five years of the registration
3. Have more than 50% of Forced vital capacity
4. Satisfies any of the following
Have a history of treatment either with Pirfenidone or Nintedanib
Have a history of treatment neither with Pirfenidone nor Nintedanib
5. Able to take medications orally
etc.
Exclusion Criteria
1. Airways obstruction
2. A serious illness or medical condition
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy<br>Forced vital capacity<br>Pulmonary function tests
- Secondary Outcome Measures
Name Time Method safety<br>efficacy<br>Safety, Efficacy<br>Pulmonary function tests, Adverse event